The maker of the blockbuster medication Humira created a “patent thicket” to illegally maintain a monopoly over the drug so it could be sold at an ever-increasing rate to the U.S. market, a major union has claimed in a newly filed antitrust class action lawsuit.

UFCW Local 1500 Welfare Fund, which is the largest union of grocery store workers in New York state, filed the proposed class action lawsuit against AbbVie and numerous other companies Monday, contending that AbbVie abused the patent process and colluded with other drug companies to improperly stave off competition for Humira in the U.S. market.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]